Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 35 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Apostolidis, Apostolos [Clear All Filters]
(2009).
(2009).
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity..
World J Urol. 31(6), 1469-74.
(2013). Male lower urinary tract symptoms: a riddle waiting to be solved..
Eur Urol. 64(3), 408-10.
(2013).
(2014).
Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?.
Curr Drug Targets. 16(11), 1187-97.
(2015). Combination Pharmacological Treatments for LUTS..
Curr Drug Targets. 16(11), 1162-4.
(2015).
(2015). Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014..
Neurourol Urodyn. 35(2), 293-8.
(2016). Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013..
Neurourol Urodyn. 35(6), 657-65.
(2016). Recommendations for future development of contractility and obstruction nomograms for women. ICI-RS 2014..
Neurourol Urodyn. 35(2), 307-11.
(2016).
(2016). Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)..
Neurourol Urodyn. 36(4), 882-893.
(2017). Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?.
BJU Int. 120(4), 459-460.
(2017). How does lower urinary tract dysfunction affect sexual function in men and women? ICI-RS 2015-Part 1..
Neurourol Urodyn. 36(4), 949-952.
(2017). How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2..
Neurourol Urodyn. 36(4), 869-875.
(2017). Neurogenic voiding dysfunction..
Curr Opin Urol. 27(3), 300-306.
(2017). The urinary microbiome and its contribution to lower urinary tract symptoms; ICI-RS 2015..
Neurourol Urodyn. 36(4), 850-853.
(2017). 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: EVALUATION AND TREATMENT OF URINARY INCONTINENCE, PELVIC ORGAN PROLAPSE AND FAECAL INCONTINENCE..
Neurourol Urodyn. 37(7), 2271-2272.
(2018). Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study..
Int J Urol. 25(8), 737-745.
(2018). The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol..
Neurourol Urodyn. 37(S4), S99-S107.
(2018). Neurogenic bowel dysfunction: Clinical management recommendations of the Neurologic Incontinence Committee of the Fifth International Consultation on Incontinence 2013..
Neurourol Urodyn. 37(1), 46-53.
(2018). Subtle errors of bladder wall thickness measurement have a significant impact on the calculation of ultrasound-estimated bladder weight. A pilot study..
Med Ultrason. 20(3), 292-297.
(2018). Is there "brain OAB" and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017..
Neurourol Urodyn. 37(S4), S38-S45.
(2018). Are psychological comorbidities important in the aetiology of lower urinary tract dysfunction-ICI-RS 2018?.
Neurourol Urodyn. 38 Suppl 5, S8-S17.
(2019).